Resources & Guides

With commercial coverage of the Zepbound single-dose pen and the savings card, eligible patients pay as little as $25 per fill, with savings capped at $1,300 per calendar year on that tier. Medicare beneficiaries have a new route from July 1, 2026: the CMS GLP-1 Bridge, which covers the Zepbound KwikPen only at $50 a month. This guide covers the insured path, prior authorization, and appeals.

The Zepbound KwikPen list price is $1,086.37 a month without insurance. The LillyDirect Self Pay Journey Program (launched February 2026) brings cash-pay vials down to $299 for 2.5mg, $399 for 5mg, and a flat $449 for every dose from 7.5mg to 15mg. This guide covers Zepbound pricing only, with no Mounjaro overlap.

The ultimate retatrutide resource hub. Learn about this investigational triple-agonist, its remarkable Phase 2 results, dosing schedules, microdosing protocols, and use our free calculator to plan your journey.

Complete Zepbound (tirzepatide) dosage chart for weight management. Covers the full 2.5 mg to 15 mg titration schedule, SURMOUNT-1 weight loss by dose, KwikPen guide, missed-dose rules, and a Zepbound vs Wegovy comparison.

Zepbound side effects guide: nausea 25-29%, diarrhea 19-23%, symptom timeline, serious warnings, and practical management tips for weight loss patients.

Zepbound contains tirzepatide, a dual agonist that activates both GLP-1 and GIP receptors simultaneously. Here is exactly what happens in your body, what SURMOUNT-1 showed at 72 weeks, and why the 5-day half-life matters for your dose schedule.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight loss, sleep apnea). Clinical trials show up to 20.9% weight loss. This guide explains the science clearly.

Both Ozempic and Wegovy contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes (max 1.0 mg) while Wegovy targets obesity (2.4 mg recommended maintenance, 7.2 mg maximum). Explore the differences.